`
`BIG plc I BTG Licenses New Prostate Cancer Drug to Cougar Biotechnology
`
`6
`
`BTG BTG
`Imagine where we can go.
`
`BTG Licenses New Prostate Cancer Drug
`to Cougar Biotechnology
`20 April 2004
`London, UK, April 20, 2004 - BTG (LSE: BGC), the global technology commercialisation company and Los Angeles-based
`Cougar Biotechnology today announced that they have signed a licence agreement in which Cougar is granted worldwide
`exclusive rights to develop and commercialise abiraterone acetate, a potential novel therapeutic for treatment of advanced
`prostate cancer. BTG will receive an upfront cash payment and will benefit from further development milestones and a
`royalty on sales. Detailed financial terms were not disclosed.
`
`Abiraterone was first synthesised at The Institute of Cancer Research (ICR) in the UK as part of a BTG-funded programme
`to discover a potent, selective, orally active drug to inhibit the key enzyme in testosterone synthesis,
`17ahydroxylase/C1720-lyase. Suppression of testosterone synthesis was subsequently demonstrated in patients with
`prostate cancer.
`
`Dr Roger Harrison, Vice President and Director of BTG’s Oncology Business Unit said, "We are very pleased to have
`secured a licensing partner with such a clear vision for the development and future clinical application of abiraterone acetate.
`This deal shows the value that we create for our partners, like ICR, and confirms that BTG is an important source of
`exciting new cancer drugs for the pharmaceutical industry."
`
`Dr. Ane Belldegrun, MD, FACS, Vice Chairman of the Board of Directors of Cougar Biotechnology said, "There is an urgent
`need for new and effective therapies for patients with advanced prostate cancer who fail first-line hormonal treatment. We
`believe that abiraterone could fill this void and serve as an important second-line hormonal agent."
`
`Alan H. Auerbach, Chief Executive Officer and President of Cougar Biotechnology added "We are pleased to be able to
`complete this licensing agreement with BTG for this novel, targeted therapy. We look forward to advancing the development
`of abiraterone during 2004."
`
`In the US, prostate cancer is the second leading cause of cancer death in men. Approximately one in six American men will
`develop prostate cancer at some time during their lifetime, and there are approximately 220,900 new cases each year. In the
`US, the annual death toll from prostate cancer is 28,900. The incidence of prostate cancer in the EU is approximately
`142,000 and some 59,700 men die of the disease.
`
`About BTG
`BTG finds, develops and commercialises emerging technologies in the life and physical sciences. These innovations are
`protected by a strong portfolio of intellectual property that BTG develops and enhances. BTG then captures the value in
`these technologies through licensing and venturing activities. From the origins of its business in 1949, BTG has
`commercialised major innovations such as Magnetic Resonance Imaging (MRI), recombinant factor IX blood-clotting protein,
`Campathfi (alemtuzumab) and Multilevel Cell (MLC) memory. BTG is quoted on the London Stock Exchange under the
`symbol "BGC" and operates from offices in London and Philadelphia, with representation in Tokyo. BTG operates through
`wholly owned subsidiaries, BTG International Ltd and BTG International Inc in the UK and USA, respectively. Further
`information about BTG can be found at www.btcn3lc.com .
`
`About Cougar Biotechnology
`Cougar Biotechnology, Inc. is a Los Angeles based private biotechnology company, established to in-license and develop
`early clinical stage drugs, with a specific focus on the field of oncology. Further information about Cougar Biotechnology can
`be found at www.cougarbiotechnoIogy.com .
`
`https://www.btgpl c.com/medi a/press-releases/btg-1 I censes-new-prostate-cancer-drug-to-cougar-bi otechnol ogy/ (cid:9)
`
`1/2
`
`WCK1087
`Wockhardt Bio AG v. Janssen Oncology, Inc.
`IPR2016-01582
`
`1
`
`
`
`4/3/2017 (cid:9)
`
`BTG plc I BTG Licenses New Prostate Cancer Drug to Cougar Biotechnology
`About The Institute of Cancer Research
`The Institute of Cancer Research is one of the worlds leading cancer research organisations and is internationally renowned
`for the quality of its science. The Institute was founded in 1909 to investigate the causes of cancer and develop new
`strategies for its prevention, diagnosis, treatment and cure. Its mission is the relief of human suffering by pursuing
`excellence in the fight against cancer. The Institute is a College of the University of London and works in a unique
`partnership with The Royal Marsden Hospital. Together they form Europe’s largest comprehensive cancer centre. The
`Institute is a charity that relies on voluntary income. Further information about The Institute of Cancer Research can be
`found at www.icr.ac.uk .
`
`Contact
`Lorraine Jones, BIG
`+44 (0)20 7575 1622
`lorraine.iones (@btaK)lc.com
`
`Alan H. Auerbach, Cougar Biotechnology, Inc.
`+1 310 443 4209
`ahauerbach( couparbiotechnology. corn
`
`Marie MacLean, Press Officer
`Institute of Cancer Research
`+44 (0)20 7153 5359
`marie. macleanicr. ac. uk
`
`UI
`
`Back to press releases
`
`At BTG we are focused on developing innovative products in specialist areas of medicine to better serve doctors and patients.
`
`' 2016 BTG International Ltd. All rights reserved. "See More, Reach Further, Treat Smarter", "Imagine where we can go", and BIG and the BTG roundel logo are trademarks
`
`of BIG International Ltd. BIG and the BTG roundel logo are registered trademarks of BTG International Ltd in the US, EU and certain other territories. Bead Block, DC Bead,
`
`DC Bead LUMI, LC Bead and LC Bead LUMI are trademarks and/or registered trademarks of Biocompatibles UK Ltd. EKOS and EkoSonic are registered trademarks of
`
`EKOS Corporation. GALIL is a trademark of Galil Medical Ltd. PneumRx is a registered trademark of PneumRx, Inc. IheraSphere is a registered trademark of Theragenics
`
`Corporation used under license by Biocompatibles UK Ltd. Varithena is a registered trademark of Provensis Ltd. CroFab and DigiFab are registered trademarks of BTG
`
`International Inc. Vistogard is a registered trademark of Wellstat Therapeutics Corporation. Voraxaze is a registered trademark of Prothencs Medicines Development Ltd.
`
`Lemtrada is a trademark of Genzyme Corporation. Zytiga is a trademark of Johnson & Johnson. Biocompatibles UK Ltd, EKOS Corporation, Gall Medical Lid, PneumRx,
`
`Inc., Protherics Medicines Development Ltd, and Provensis Ltd are all BIG International group companies. Not all products and/or indications are available in all territories.
`For prescribing information, safety information, and/or product information, go to: bead-block.com crofab.com I dcbead.com I dcbeadlumi.com I digifsb.us I ekoscorc.com I
`ctalilmedical,corn I lcbead.com I Icbeadlumi.com I Iemtrada.com I pneumrx.com I therasphere.com I varithena.com I vistogard.com I voraxaze.com I zytipa.com
`
`ogy/ (cid:9)
`
`2/2
`
`2
`
`